{
    "Trade/Device Name(s)": [
        "FastPack\u00ae Testo Immunoassay",
        "Total Testosterone Immunoassay"
    ],
    "Submitter Information": "Qualigen, Inc.",
    "510(k) Number": "K101388",
    "Predicate Device Reference 510(k) Number(s)": [
        "K021972"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "February 3, 2011",
    "Summary Letter Received Date": "February 4, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1690",
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Total testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "K2 EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "K2 EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "FastPack\u00ae Analyzer",
        "FastPack\u00ae System"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive chemiluminescence assay",
        "Paramagnetic particle immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for FastPack\u00ae Testo Immunoassay for quantitative determination of total testosterone in serum and plasma using a chemiluminescent immunoassay on the FastPack\u00ae System",
    "Indications for Use Summary": "For in-vitro quantitative determination of total testosterone in human serum or plasma as an aid in diagnosis and management of conditions involving androgen excess or deficiency, for use with the FastPack\u00ae System",
    "fda_folder": "Clinical Chemistry"
}